We assessed whether montelukast or formoterol provides additive effects to asthmatics not controlled on inhaled corticosteroids, by studying patients who were considered to be genetically susceptible to b 2 -receptor down regulation and subsensitivity, and who expressed the homozygous glycine-16 b 2 -receptor genotype. Methods Fifteen corticosteroid-treated, mild to moderate persistent asthmatics received montelukast 10 mg once daily or formoterol 9 m g twice daily for 2 weeks, separated by a 2-week placebo run-in and washout, in a double-blind, doubledummy, randomized crossover design. Bronchoprotection against adenosine monophosphate (AMP) challenge (primary endpoint), spirometry and blood eosinophils were measured at trough after placebo, first and last doses. Results For AMP PC 20 vs placebo, there were sustained significant ( P < 0.05) doubling dilution improvements following first (1.1; 95% CI 0.4, 1.9) and last (1.0; 95% CI 0.3, 1.8) doses of montelukast, and following first (1.3; 95% CI 0.1, 2.6) but not last (0.3; 95% CI -0.9, 1.6) doses of formoterol. Blood eosinophils ( ¥ 10 6 l -1 ) were significantly ( P < 0.05) suppressed after the last dose of montelukast ( -71; 95% CI -3, -140) compared with placebo, while formoterol exhibited a nonsignificant rise (20; 95% CI -92, 132). Neither treatment significantly improved FEV 1 , FEF or PEF after 2 weeks. Conclusions In genetically susceptible patients with the homozygous glycine-16 genotype, montelukast, but not formoterol, conferred sustained anti-inflammatory properties in addition to inhaled corticosteroid, which were dissociated from changes in lung function after 2 weeks. Thus, assessing lung function may miss potentially beneficial anti-inflammatory effects of montelukast when used as add-on therapy.
Introduction
Long-acting b 2 -agonists such as formoterol and salmeterol are recommended as add-on therapy in asthma when inhaled corticosteroids (ICS) provide suboptimal symptom control [1, 2] . Their addition has been shown to provide equivalent asthma control compared with using a higher dose of ICS alone [3, 4] . However, when given on a regular basis in patients taking ICS, long-acting b 2 -agonists produce downregulation and desensitization of airway b 2 -adrenoceptors, resulting in tolerance to their bronchoprotective and bronchodilator effects [3, [5] [6] [7] [8] [9] .
In vitro studies have demonstrated that susceptibility to b 2 -agonist-induced downregulation is associated with allelic polymorphisms of the b 2 -adrenoceptor at positions 16 and 27. At position 16, the homozygous glycine genotype confers increased susceptibility compared with either homozygous arginine or heterozygous genotypes [10, 11] . Polymorphisms at position 16 are also dominant over those at 27 in determining susceptibility. Furthermore, the homozygous glycine-16 genotype has been shown in vivo to predispose to bronchodilator desensitization in asthmatic patients receiving regular inhaled formoterol [12] . Other data have suggested the homozygous glycine-16 genotype to be associated with blunting of the acute bronchodilator reversibility to salbutamol [13, 14] . In contrast, in patients with the homozygous arginine-16 genotype, the use of regular salbutamol was associated with worse outcomes of asthma control [15, 16] . As approximately 40% of the population possess the homozygous glycine-16 genotype [17, 18] , one could argue that this is a potentially clinically relevant determinant of response to long-acting b 2 -agonists.
Leukotriene receptor antagonists (LTRA), such as montelukast, exhibit anti-inflammatory properties and are an alternative to long-acting b 2 -agonists as add-on therapy [19] . LTRA have been shown to exhibit additive effects to low-dose ICS [20] as well as facilitating dose tapering in patients on high-dose ICS [21, 22] . The objective of the present study was to evaluate, in genetically susceptible patients with the glycine-16 genotype, whether montelukast or formoterol provided additive effects on surrogate inflammatory markers and lung function in patients suboptimally controlled on ICS.
The primary endpoint was adenosine monophosphate (AMP) bronchial challenge, which causes bronchoconstriction indirectly by release of inflammatory mediators from primed airway mast cells [23] . AMP has been shown to be more sensitive in detecting anti-inflammatory effects of ICS than a direct bronchial challenge such as methacholine and is probably more clinically relevant to everyday indirect stimuli [24] [25] [26] . Furthermore, as there are b 2 -adrenoceptors on mast cells, effects of long-acting b 2 -agonists on AMP may also be considered as a surrogate for in vivo anti-inflammatory activity, as Nightingale et al. [27] demonstrated in as study showing differential effects of formoterol on AMP and histamine challenge. We also assessed other surrogate inflammatory markers including blood eosinophil count and nitric oxide (NO) [28, 29] , as well as spirometry and domiciliary diary cards. All measurements were made at trough at the end of the usual dosing interval, 12 h after last dose of formoterol and 24 h after montelukast, when the airway would be at its most vulnerable to bronchoconstrictor stimuli.
Patients and methods
Fifteen nonsmoking, mild to moderate persistent asthmatics (5M, 10F; mean ± SEM age 35.1 ± 2.9 years; FEV 1 79 ± 4.0%; FEF 51 ± 4.7%), who had daily symptoms despite being on inhaled corticosteroids (ICS, median dose 500 m g day -1 ; one on fluticasone, five on budesonide, nine on beclomethasone) and requiring at least two puffs day -1 of rescue bronchodilator, were recruited to completion. All patients exhibited airway hyper-responsiveness to AMP challenge testing with a provocation concentration producing 20% fall in FEV 1 (PC 20 ) of less than 200 mg ml -1 (geometric mean 18.7 ± 5.7 mg ml -1 ) prior to the initial run-in period. All patients had the homozygous glycine genotype at position 16. For position 27, two patients were homozygous for glutamine, four were homozygous for glutamic acid, and the remaining nine were heterozygous (i.e. glutamic acid and glutamine). In view of the small numbers of patients with each genotype at position 27, a formal statistical comparison was not made. Genotypes were determined using a previously described method [12] . The study was approved by Tayside Medical Research Ethics Committee. All patients gave written informed consent.
In a randomized placebo-controlled, double-blind, double-dummy, crossover design, patients received 9 m g inhaled formoterol twice daily (b.i. At the beginning of the trial, a pharmacist sealed the treatments and instruction sheets in envelopes. Compliance was assessed by tick charts and tablet counts. Data with more than 90% overall compliance were considered to be assessable; this was attained in all cases.
Laboratory measurements including AMP, spirometry, exhaled NO measurements and blood eosinophil counts were performed in the morning, after placebo, and first and last doses of randomized treatment. Rescue medication was withheld for 12 h prior to each visit. AMP challenge testing was performed as previously described [30] . If PC 20 was not reached after the highest dose of 800 m g ml -1 , a censored value of 1600 mg ml -1 was assigned. NO was measured using a LR2000 NO gas analyser (Logan Research, Rochester, UK) as described elsewhere [31] under standardized conditions [32] . Spirometry was performed according to American Thoracic Society criteria [33] using a Vitalograph Compact spirometer (Vitalograph Ltd, Bucks, UK). Eosinophil count was measured using an SE-9000 Haematology analyser (Sysmex UK Ltd, Bucks, UK). Domiciliary peak expiratory flow was measured with a Mini-Wright peak flow meter (Clement Clarke, Essex, UK), with asthma symptoms rated according to a four-point scale: 0 (no symptoms) to 3 (severe symptoms), and rescue bronchodilator requirements were recorded twice daily.
Statistical analysis
The study was designed with at least 80% power to detect a 1.0 doubling-dose difference in AMP PC 20 from placebo, with the alpha-error set at 0.05 (two-tailed), and powered to show an add-on effect to ICS (i.e. vs. placebo) but not to compare treatments. The data for AMP PC 20 were log-transformed to normalize the distribution before analysis. Mean of the last 5 days' domiciliary data of each treatment period were analysed. Comparisons between randomized treatments and placebo were made by analysis of variance followed by multiple range testing with Bonferroni's correction [set at 95% confidence interval (CI)] to obviate multiple pair-wise comparisons (Statgraphics statistical software package; STSC Software Publishing Group, Rockville, MD, USA).
Results
There were no significant carryover effects between placebo values prior to each randomized treatment after run-in and washout for any of the measurements (Table 1) . Consequently, a pooled placebo value was used for the purposes of comparing with randomized treatments.
Surrogate inflammatory markers
For AMP PC 20 compared with placebo, there were sustained significant ( P < 0.05) doubling-dilution improvements following the first (1.1; 95% CI 0.4, 1.9) and last doses (1.0; 95% CI 0.3, 1.8) of montelukast ( Figure 1 , Table 2 ). Formoterol showed significant improvement after the first (1.3; 95% CI 0.1, 2.6) but not after the last dose (0.3; 95% CI -0.9, 1.6). The individual data for AMP responses showed no differences between the genotypes at position 27, with most individuals exhibiting loss of protection between the first and last doses of formoterol (data not shown). After 2 weeks, montelukast induced a significant ( P < 0.05) reduction in blood eosinophil ( ¥ 10 6 l -1 ) count after 2 weeks ( -71; 95% CI -3, -140) compared with placebo, while there was a nonsignificant increase after 2 weeks of formoterol (20; 95% CI -92, 132) (Figure 2 ). There were no significant effects on NO for montelukast or formoterol compared with placebo after 2 weeks (Figure 2 ).
Laboratory lung function
There were significant improvements after the first dose of formoterol compared with placebo for FEF and PEF, but not for FEV 1 (Figure 3) . No significant differences were found between placebo vs. the last dose of formoterol, or vs. the first or last dose of montelukast for any lung function parameters (Table 2) .
Domiciliary diary cards
Compared with placebo, both treatments showed significant (P < 0.05) improvements in daytime rescue use (i.e. recorded pm) but not for any other endpoints (Table 3) . Previous in vitro and in vivo studies have shown that the susceptibility to tolerance conferred by the glycine-16 genotype overcomes any resistance conferred by the glutamic acid-27 genotype for patients who exhibit this haplotype in combination. However, the situation is potentially even more complex when taking into account all of the different haplotypes with multiple singlenucleotide polymorphisms. We were unable to determine these complex haplotypes because our database is only characterized according to polymorphisms at position 16 and 27.
It was shown in a retrospective analysis by Drysdale et al. [40] that these unique interactions of multiple polymorphisms within a haplotype may determine the acute bronchodilator response to a single dose of salbutamol. Further pharmacogenetic studies are required to prospectively evaluate whether such haplotypes determine the development of tolerance with chronic dosing of longacting b 2 -agonists for functional antagonism against bronchoconstriction. Indeed, our data revealed marked tolerance following formoterol, which would vindicate the selection of patients with the glycine-16 genotype.
Our sample size precluded formal statistical comparison of the different genotypes at position 27, but we did not observe any obvious trends from inspection of indi- ), laboratory peak expiratory flow (PEFlab), domiciliary morning/evening peak expiratory flow (PEFam/pm), daytime/night-time symptom score (SYMam/pm) and daytime/night-time rescue bronchodilator requirement (RESam/pm). *Denotes a significant difference between pooled placebo and randomized treatments. Table 3 Means (95% confidence limits) for domiciliary diary card data for pooled placebo and each randomized treatment.
Discussion
The results of the present study showed sustained bronchoprotection against AMP challenge with montelukast but not formoterol in addition to ICS in genetically susceptible patients who would be expected to fare worse with a long-acting b 2 -agonist. This observation is in keeping with studies using indirect challenges in nongenotyped patients, as reported by Wilson et al. [34] with AMP in steroid-treated patients, and by Villaran et al. [35] and Edelman et al. [36] with exercise in mostly steroidnaive patients, where comparisons were made between salmeterol and montelukast. However using the direct stimulus of methacholine challenge in steroid-treated patients with the homozygous glycine-16 genotype, formoterol 9 mg b.i.d. and zafirlukast 20 mg b.i.d. both exhibited significant residual trough protection after 1 week [37] . The degree of formoterol-induced tolerance for methacholine protection may not be influenced by polymorphisms at position 16 or 27. This is perhaps not surprising given that tolerance to bronchoprotective effects of b 2 -agonists is more pronounced for indirect than direct stimuli [38] . In order to fully understand the pharmacogenetics of b 2 -receptor regulation, it is important to consider the potential role of endogenous catecholamines in the basal state. In vitro data from transfected cell lines has shown that the glycine-16 genotype is more susceptible to b 2 -agonist-induced downregulation than the arginine-16 genotype. According to Liggett, the dynamic baseline model would result in patients with the glycine-16 genotype being susceptible to pretrial downregulation by endogenous catecholamines, such that their receptors would already be downregulated in the basal state, and therefore less prone to further downregulation by subsequent exogenous b 2 -agonist therapy [39] . In contrast, the arginine-16 genotype, according to the dynamic model, would be relatively resistant to the pretrial effects of vidual data (not shown). It is important to point out that there is linkage disequilibrium, with the haplotype combination of homozygous glutamic acid at position 27 always being associated with homozygous glycine at position 16, although the homozygous glycine-16 genotype may occur in combination with any other genotype at position 27.
The degree of tolerance between the first and last dose protection against AMP challenge shown here for formoterol (a 1.0 doubling-dilution trough difference) concurs with previous data reported by Wilson et al. [34] for salmeterol (1.2 doubling-dilution trough difference) and with Aziz et al. [5] for formoterol (1.9 doubling-dilution peak difference) in nongenotyped patients, the latter receiving 18 mg twice daily, as opposed to 9 mg twice daily used here. This in turn would suggest that the bronchoprotective tolerance occurs irrespective of the position-16 genotype for AMP challenge.
The addition of montelukast, but not formoterol, significantly reduced peripheral blood eosinophils but did not significantly reduce exhaled nitric oxide, although the latter showed a trend. A similar additive reduction of blood eosinophils with montelukast has been reported by Wilson et al. and Laviolette et al. [20] . Furthermore, while Wilson et al. showed no additive effects of montelukast on exhaled NO [34] , in another study zafirlukast as add-on therapy exhibited a small but significant effect [37] . Montelukast as monotherapy has also been shown to suppress NO [29, 41] . In this respect, it is recognized that low-dose ICS exhibit a maximal suppression of exhaled nitric oxide to near-normal values [25] . In addition, Tamaoki et al. showed that adding pranlukast, compared with placebo, facilitated a halving of the dose of ICS without any increase in levels of NO or serum eosinophilic cationic protein [21] .
In terms of laboratory lung function, neither treatment afforded significant improvements in FEV 1 at either dose, although a significant increase in FEF and PEF was only shown after first-dose formoterol. For domiciliary measurements, no significant improvement in morning or evening domiciliary PEF or symptoms were found with montelukast or formoterol. Improvements in laboratory and domiciliary pulmonary function have been reported as add-on therapy in comparative studies with salmeterol, formoterol, montelukast or zafirlukast [34, 37, [41] [42] [43] .
The effects on lung function are always biased towards a bronchodilator such as a long-acting b 2 -agonist, especially when patients are selected according to salbutamol reversibility as an inclusion criteria [42] [43] [44] . Our patients were not selected on the basis of bronchodilator reversibility. Nonetheless, the significant improvements in PEF and FEF after the first dose of formoterol were not sustained after 2 weeks, in keeping with their genetic susceptibility to developing bronchodilator tolerance [12] . However, it is possible that we have missed a small but sustained improvement in lung function, as our study was not powered on this endpoint.
The lack of any additional improvement with montelukast on domiciliary or laboratory PEF in our study is similar to that described by Robinson et al. [45] in more severe patients, although their patients were already on maximal therapy and they did not evaluate any inflammatory endpoints. Our data showing additive significant effects on AMP and eosinophils with montelukast emphasize the point that assessing lung function only will miss potentially beneficial anti-inflammatory effects of leukotriene receptor antagonists.
In summary, we have shown that in patients genetically predisposed to b 2 -adrenoceptor desensitization with the glycine-16 genotype, montelukast, but not formoterol, exhibited sustained anti-inflammatory properties additional to inhaled corticosteroid in terms of bronchoprotection and reduction of blood eosinophils, which were dissociated from any changes in lung function after 2 weeks. Montelukast may therefore be a suitable alternative to a long-acting b 2 -agonist in patients who are predisposed to tolerance. Moreover, assessing lung function may miss potential anti-inflammatory benefits of montelukast when used as add-on therapy.
